TNF Pharmaceuticals (TNFA) 10-Q/A 13 Jul 18 2017 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 14, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Akers Biosciences, Inc.
Entity Central Index Key	1,321,834
Document Type	10-Q/A
Document Period End Date	Jun. 30, 2017
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-Q/A (this “Form 10-Q/A”) amends and restates certain items noted below in the Quarterly Report on Form 10-Q of Akers Biosciences, Inc. (the “Company”) for the quarterly period ended June 30, 2017, as originally filed with the Securities and Exchange Commission on August 14, 2017 (the “Original Filing”). This Form 10-Q/A amends the Original Filing to reflect the correction of errors in the previously reported quarterly period ended June 30, 2017 financial statements related to the Company’s revenue and expense recognition. See Note 2 to the Condensed Consolidated Financial Statements included in Part I, Item 1, for additional information and a reconciliation of the previously reported amounts to the restated amounts. For the convenience of the reader, this Form 10-Q/A sets forth the Original Filing, as amended, in its entirety; however, this Form 10-Q/A amends and restates only the following financial statements and disclosures that were impacted from the correction of the error: ● Part I, Item 1 – Financial Statements ● Part I, Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations ● Part I, Item 4 – Controls and Procedures ● Part II, Item 1A – Risk Factors ● Signatures The Company’s Chief Executive Officer and Chief Financial Officer have provided new certifications dated as of the date of this filing in connection with this Form 10-Q/A (Exhibits 31.1, 31.2, 32.1 and 32.2), and the Company has provided its condensed consolidated financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibit 101. Except as described above, no other changes have been made to the Original Filing. This Form 10-Q/A speaks as of the date of the Original Filing and does not reflect events that may have occurred after the date of the Original Filing, or modify or update any disclosures that may have been affected by subsequent events. The Company is also concurrently filing an amended Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2017 and 2016 and an amended Annual Report for the years ended December 31, 2017 and 2016 to restate those previously issued financial statements.
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,901,245
Trading symbol	AKER
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 197,175	$ 72,700
Marketable Securities	1,011,625	50,001
Trade Receivables, net	927,534	601,271
Trade Receivables - Related Party, net		31,892
Deposits and other receivables	13,090	23,782
Inventories, net	2,228,839	2,036,521
Prepaid expenses	147,526	168,277
Prepaid expenses - Related Party	317,439	202,500
Total Current Assets	4,843,228	3,186,944
Non-Current Assets
Prepaid expenses - Related Party	108,353	270,183
Property, Plant and Equipment, net	260,756	259,392
Intangible Assets, net	1,216,221	1,301,775
Other Assets	71,143	66,813
Total Non-Current Assets	1,656,473	1,898,163
Total Assets	6,499,701	5,085,107
Current Liabilities
Trade and Other Payables	1,501,641	1,463,363
Trade and Other Payables - Related Party	33,911	234,067
Total Current Liabilities	1,535,552	1,697,430
Total Liabilities	1,535,552	1,697,430
STOCKHOLDERS' EQUITY
Convertible Preferred Stock, No par value, 50,000,000 shares authorized, no shares issued and outstanding as of June 30, 2017 and December 31, 2016
Common Stock, No par value, 500,000,000 shares authorized, 8,901,245 and 5,452,545 issued and outstanding as of June 30, 2017 and December 31, 2016	104,624,119	100,891,786
Deferred Compensation	(14,163)	(24,572)
Accumulated Deficit	(99,646,816)	(97,479,537)
Accumulated Other Comprehensive Income	1,009
Total Stockholders' Equity	4,964,149	3,387,677
Total Liabilities and Stockholders' Equity	$ 6,499,701	$ 5,085,107

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Convertible preferred stock, no par value
Convertible preferred stock, shares authorized	50,000,000	50,000,000
Convertible preferred stock, shares issued
Convertible preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	8,901,245	5,452,545
Common stock, shares outstanding	8,901,245	5,452,545

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Product Revenue	$ 1,096,925	$ 956,486	$ 1,740,111	$ 1,694,510
Product Revenue - Related party	(24,064)
Total Revenues	1,072,861	956,486	1,740,111	1,694,510
Cost of Sales:
Product Cost of Sales	(290,591)	(276,848)	(549,312)	(476,876)
Gross Income	782,270	679,638	1,190,799	1,217,634
Administrative Expenses	829,929	816,244	1,620,457	1,739,806
Sales and Marketing Expenses	354,889	513,430	911,545	1,238,754
Sales and Marketing Expenses - Related Party	61,502		93,781
Research and Development Expenses	290,841	321,989	639,283	685,280
Research and Development Expenses - Related Party	22,994		22,994
Amortization of Non-Current Assets	42,777	42,777	85,554	85,554
Loss from Operations	(820,662)	(1,014,802)	(2,182,815)	(2,531,760)
Other (Income)/Expenses
Foreign Currency Transaction (Gain)/Loss	978	2,562	(9,367)	4,817
Interest and Dividend Income	(3,632)	(8,432)	(6,169)	(18,716)
Other Income
Total Other Income	(2,654)	(5,870)	(15,536)	(13,899)
Loss Before Income Taxes	(818,008)	(1,008,932)	(2,167,279)	(2,517,861)
Income Tax Benefit
Net Loss	(818,008)	(1,008,932)	(2,167,279)	(2,517,861)
Other Comprehensive Income/(Loss)
Net Unrealized Gain/(Loss) on Marketable Securities	852	(2,006)	1,009	6,528
Total Other Comprehensive Income/(Loss)	852	(2,006)	1,009	6,528
Comprehensive Loss	$ (817,156)	$ (1,010,938)	$ (2,166,270)	$ (2,511,333)
Basic and diluted loss per common share	$ (0.09)	$ (0.19)	$ (0.27)	$ (0.46)
Weighted average basic and diluted common shares outstanding	8,882,326	5,427,261	7,943,168	5,426,153

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholder's Equity - 6 months ended Jun. 30, 2017 - USD ($)	Common Stock [Member]	Deferred Compensation [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Total
Balance at Dec. 31, 2016	$ 100,891,786	$ (24,572)	$ (97,479,537)		$ 3,387,677
Balance, shares at Dec. 31, 2016	5,452,545
Net loss					(2,167,279)
Public offering of common stock, net of offering costs of $494,406	$ 1,652,994				1,652,994
Public offering of common stock, net of offering costs of $494,406, shares	1,789,500
Private offering of common stock, net of offering costs of $267,443	$ 1,760,317				1,760,317
Private offering of common stock, net of offering costs of $267,443, shares	1,448,400
Exercise of warrants for common stock	$ 301,200				301,200
Exercise of warrants for common stock, shares	200,800
Amortization of deferred compensation		10,409			10,409
Issuance of non-qualified stock options to key employees	10,184				10,184
Issuance of non-qualified stock options to services to non-employees	2,183				2,183
Issuance of restricted stock for services to non-employees	$ 5,455				5,455
Issuance of restricted stock for services to non-employees, shares	10,000
Net unrealized gain on marketable securities				1,009	1,009
Balance at Jun. 30, 2017	$ 104,624,119	$ (14,163)	$ (99,646,816)	$ 1,009	$ 4,964,149
Balance, shares at Jun. 30, 2017	8,901,245

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Changes in Stockholder's Equity (Parenthetical)	Jun. 30, 2017USD ($)
Public Offering [Member]
Net offering cost	$ 494,406
Private Offering[Member]
Net offering cost	$ 267,443

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss for the year	$ (2,167,279)	$ (2,517,861)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued income on marketable securities	(1,001)	8,927
Depreciation and amortization	121,381	113,906
Reserve and write-off for obsolete inventory	21,542
Allowance for doubtful accounts	46,239	146,196
Fair value of restricted common stock issued for services	15,864	18,243
Share based compensation to employees - options	10,184
Share based compensation to non-employees - options	2,183	8,241
Changes in assets and liabilities:
Increase in trade receivables	(372,502)	(79,906)
Decrease in trade receivables - related party	31,892
Decrease in deposits and other receivables	10,692	31,196
Increase in inventories	(213,860)	(85,588)
Decrease in prepaid expenses	20,752	43,933
Decrease in prepaid expenses - related party	46,890
Increase in other assets	(4,330)
Increase/(decrease) in trade and other payables	38,278	(103,029)
Decrease in trade and other payables - related party	(200,156)
Net cash used in operating activities	(2,593,231)	(2,415,742)
Cash flows from investing activities
Purchases of property, plant and equipment	(37,191)	(81,462)
Purchases of marketable securities	(2,705,168)	(27,643)
Proceeds from sale of marketable securities	1,745,554	2,502,319
Net cash (used in)/provided by investing activities	(996,805)	2,393,214
Cash flows from financing activities
Net proceeds from issuance of common stock	3,413,311
Net proceeds from exercise of warrants for common stock	301,200
Net cash provided by financing activities	3,714,511
Net increase/(decrease) in cash	124,475	(22,528)
Cash at beginning of period	72,700	402,059
Cash at end of period	197,175	379,531
Supplemental Schedule of Non-Cash Financing and Investing Activities
Issuance of a restricted common stock grant for services	5,455
Issuance of a restricted common stock grant to an officer		54,725
Net unrealized gains on marketable securities	$ 1,009	$ 6,528

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Note 1 - Nature of Business (a) Reporting Entity The accompanying financial statements have been prepared by Akers Biosciences, Inc. (“Akers” or the “Company”), a company domiciled in the United States of America. The address of the Company’s registered office is 201 Grove Road, West Deptford, New Jersey, 08086. The Company is incorporated in the United States of America under the laws of the State of New Jersey. The consolidated financial statements include two dormant subsidiaries, Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation. All material intercompany transactions have been eliminated upon consolidation. (b) Nature of Business The Company’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main products are a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a rapid disposable breath test that measures Free Radical activity in the human body. When the Company enters into an agreement with a new distributor it typically requires an upfront licensing fee to be paid for the right to sell the Company’s products in specific markets.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	6 Months Ended
	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Restatement of Previously Issued Financial Statements	Note 2 – Restatement of Previously Issued Financial Statements As previously disclosed, the Company determined that certain revenue transactions did not qualify for revenue recognition under generally accepted accounting principles. In the process of this determination, the Company discovered information that existed at June 30, 2017 which affected the revenue and an obligation. The Company concluded that the impact of applying corrections for these errors and misstatements on the condensed consolidated financial statements as of and for the three and six months ended June 30, 2017 is material. As a result, the Company is restating its condensed consolidated financial statements for the periods impacted. See below for a reconciliation of the previously reported amounts to the restated amounts. The table below sets forth the consolidated balance sheets, including the balances originally reported, corrections and the as restated balances: As of June 30, 2017 As Reported Correction As Restated Trade Receivables – Related Party, net $ 125,001 $ (125,001 ) $ - Inventories, net 2,166,699 62,140 2,228,839 Total Current Assets 4,906,089 (62,861 ) 4,843,228 Total Assets 6,562,562 (62,861 ) 6,499,701 Trade and Other Payables 1,413,141 88,500 1,501,641 Total Current Liabilities 1,447,052 88,500 1,535,552 Total Liabilities 1,447,052 88,500 1,535,552 Accumulated Deficit (99,495,455 ) (151,361 ) (99,646,816 ) Total Stockholder’s Equity 5,115,510 (151,361 ) 4,964,149 Total Liabilities and Stockholders’ Equity 6,562,562 (62,861 ) 6,499,701 The table below sets for the consolidated statements of income, including the amounts originally reported, corrections, and the restated amounts: For the three months ended June 30, 2017 As Reported Correction As Restated Product revenue $ 1,097,295 $ (370 ) $ 1,096,925 Product revenue – Related party 100,567 (124,631 ) (24,064 ) Product Cost of Sales (264,231 ) (26,360 ) (290,591 ) Gross Income 933,631 (151,361 ) 782,270 Loss from Operations (669,301 ) (151,361 ) (820,662 ) Loss Before Income Taxes (666,647 ) (151,361 ) (818,008 ) Net Loss Attributable to Common Stockholders (666,647 ) (151,361 ) (818,008 ) Comprehensive Loss (665,795 ) (151,361 ) (817,156 ) Loss per share $ (0.08 ) $ (0.01 ) $ (0.09 ) For the six months ended June 30, 2017 As Reported Correction As Restated Product revenue $ 1,740,481 $ (370 ) $ 1,740,111 Product revenue – Related party 124,631 (124,631 ) - Product Cost of Sales (522,952 ) (26,360 ) (549,312 ) Gross Income 1,342,160 (151,361 ) 1,190,799 Loss from Operations (2,031,454 ) (151,361 ) (2,182,815 ) Loss Before Income Taxes (2,015,918 ) (151,361 ) (2,167,279 ) Net Loss Attributable to Common Stockholders (2,015,918 ) (151,361 ) (2,167,279 ) Comprehensive Loss (2,014,909 ) (151,361 ) (2,166,270 ) Loss per share $ (0.25 ) $ (0.02 ) $ (0.27 ) The table below sets forth the condensed consolidated statements of shareholders’ equity, including the balances originally reported, corrections and the as restated balances: For the six months ended June 30, 2017 As Reported Correction As Restated Net loss, for the six months ended June 30, 2017 $ (2,015,918 ) $ (151,361 ) $ (2,167,279 ) Accumulated Deficit, as of June 30, 2017 (99,495,455 ) (151,361 ) (99,646,816 ) Total Equity, as of June 30, 2017 5,115,510 (151,361 ) 4,964,149 The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances: For the six months ended June 30, 2017 As Reported Correction As Restated Net loss $ (2,015,918 ) $ (151,361 ) $ (2,167,279 ) (Increase)/decrease in trade receivables – related party (93,109 ) 125,001 31,892 Increase in inventories (151,720 ) (62,140 ) (213,860 ) Increase/(decrease) in trade and other payables (50,222 ) 88,500 38,278 Net cash used in operating activities (2,593,231 ) - (2,593,231 ) The restatement had no impact on cash flows from investing activities or financing activities. In addition to the restated condensed consolidated financial statements, the information contained in Notes 3, 6, 7, 10, 13, 15, 16, 17, and 20 has been restated.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 3 - Basis of Presentation and Significant Accounting Policies (a) Basis of Presentation The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP). Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed. As such, the information included in these financial statements should be read in conjunction with the audited financial statements as of and for the years ended December 31, 2016 and 2015 included in the Company’s 2016 Form 10-K. In the opinion of the management, these consolidated financial statements include all adjustments, consisting of only normal recurring nature, necessary for a fair statement of the financial position of the Company as of June 30, 2017 and its results of operations and cash flows for the three and six months ended June 30, 2017 and 2016. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2017. The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements. (b) Use of Estimates and Judgments The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for revenue recognition, allowances for doubtful accounts, inventory write-downs, impairment of intangible assets and valuation of share based payments. (c) Functional and Presentation Currency These consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information presented in U.S. Dollars has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from loans and cash balances denominated in Foreign Currencies, are recorded in the consolidated statement of operations and comprehensive loss. (d) Comprehensive Income (Loss) The Company follows Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 220 in reporting comprehensive income (loss). Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. (e) Cash and Cash Equivalents Cash and cash equivalents comprise cash balances. The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents. Bank overdrafts are shown as part of trade and other payables in the consolidated balance sheet. (f) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities. The fair value of marketable securities is described in Note 3(c). (g) Fair Value Measurement – Marketable Securities The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include ● quoted prices for similar assets or liabilities in active markets; ● quoted prices for identical or similar assets or liabilities in inactive markets; ● inputs other than quoted prices that are observable for the asset or liability; ● inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs. (h) Trade Receivables, Trade Receivables – Related Party and Allowance for Doubtful Accounts (restated) The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature. The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. As of June 30, 2017 and December 31, 2016, allowances for doubtful accounts for trade receivables were $192,435 and $1,010,196. Bad debt expenses for trade receivables were $5,380 and $47,741 for the three month and six months ended June 30, 2017 and $146,196 for the three and six months ended June 30, 2016. (j) Concentration of Credit Risk (restated) The Company is exposed to credit risk in the normal course of business primarily related to trade receivables and cash and cash equivalents. All of the Company’s cash is maintained with Fulton Bank of New Jersey, Bank of America, NA and PayPal. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company placed $182,913 and $67,865 with Fulton Bank of New Jersey, $10,222 and $795 with Bank of America, NA and $4,040 and $4,040 with PayPal as of June 30, 2017 and December 31, 2016. No losses have been incurred in these accounts. Three customers accounted for 76% of trade receivables as of June 30, 2017. In order to limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition. (k) Inventories Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overheads based on normal operating capacity. (l) Property, Plant and Equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the consolidated statement of operations and comprehensive loss. Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Leasehold Improvements Shorter of the remaining lease or estimated useful life Depreciation methods, useful lives and residual values are reviewed at each reporting date. (m) Intangible Assets (i) Patents and Trade Secrets The Company has developed or acquired several diagnostic tests that can detect the presence of various substances in a person’s breath, blood, urine and saliva. Propriety protection for the Company’s products, technology and process is important to its competitive position. As of June 30 (ii) Patent Costs Costs associated with applying for patents are capitalized as patent costs. Once the patents are approved, the respective costs are amortized over their estimated useful lives (maximum of 17 years) on a straight-line basis. Patent pending costs for patents that are not approved are charged to operations the year the patent is rejected. In addition, patents may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life. (iii) Other Intangible Assets Other intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5 (n) Recoverability of Long Lived Assets In accordance with FASB ASC 360-10-35 “Impairment or Disposal of Long-lived Assets”, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges) and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets. (o) Investments In accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company’s ability to significantly influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the time of the investment based upon several factors including, but not limited to the following: a) Representation on the Board of Directors b) Participation in policy-making processes c) Material intra-entity transactions d) Interchange of management personnel e) Technological dependencies f) Extent of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small. The Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the cost method. Investments recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company’s ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for using the cost method to the equity method of valuation. (p) Revenue Recognition In accordance with FASB ASC 605, the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) the collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales when title passes to the customer based on shipping terms. The Company typically does not accept returns nor offer charge backs or rebates except for certain distributors. Revenue recorded is net of any discount, rebate or sales return. The accrual for estimated sales returns was $- as of June 30, 2017 and December 31, 2016. The Company implemented a standard dealer cost model during the year ended December 31, 2016 which includes a provision for rebates to the distributors under limited circumstances. The Company established an accrual of $24,294 and $41,120, which is a reduction of revenue as of June 30, 2017 and December 31, 2016. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $67,855 and $170,678 during the three and six months ended June 30, 2017 and $115,685 and $215,653 for the three and six months ended June 30, 2016 for rebates, which is included as a reduction of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. License fee revenue is recognized on a straight-line basis over the term of the license agreement. When the Company enters into arrangements that contain more than one deliverable, the Company allocates revenue to the separate elements under the arrangement based on their relative selling prices in accordance with FASB ASC 605-25. (q) Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. (r) Shipping and Handling Fees and Costs The Company charges actual shipping plus a handling fee to customers, which amounted to $15,049 and $14,387 for the three months ended June 30, 2017 and 2016 and to $33,469 and $30,432 for the six months ended June 30, 2017 and 2016. These fees are classified as part of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as part of the cost of net revenue, which amounted to $31,393 and $47,570 for the three and six months ended June 30, 2017 and to $47,018 and $68,732 for the three and six months ended June 30, 2016. (s) Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. (t) Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over shorter of the period over which services are to be received or the vesting period. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees”. Under FASB ASC 505-50, the Company determines the fair value of the stock warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock-based awards to non-employees on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the period which services are to be received. At the end of each financial reporting period, prior to vesting or prior to completion of services, the fair value of equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurement until the equity based payments are fully vested or the service is completed. (u) Basic and Diluted Earnings per Share of Common Stock Basic earnings per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share are computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock. (v) Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation. (w) Recently Adopted Accounting Pronouncements As of June 30, 2017 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements. (x) Recently Issued Accounting Pronouncements Not Yet Adopted As the Company is an emerging growth company, it has elected to adopt recently issued standards based on effective dates applicable to nonpublic entities. All effective dates as mentioned in the following paragraphs refer to that applicable to nonpublic entities. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 and interim reporting periods within annual reporting periods beginning after December 15, 2019. Early application is permitted as of annual reporting periods beginning after December 15, 2016 including interim reporting periods within that reporting period. The Company is currently evaluating the effect of the amendments but it does not anticipate a material impact of its financial statements. The Company expects to use the modified retrospective adoption method. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation

Management Plan

Management Plan	6 Months Ended
	Jun. 30, 2017
Management Plan
Management Plan	Note 4 – Management Plan Historically, the Company has relied upon public offerings and private placements of common stock to raise operating capital. During the three months ending March 31, 2017, the Company raised approximately $1.7 million in a public offering and an additional $1.8 million from a private placement of common stock (Note 11). As of August 10, 2017, the Company had cash and marketable securities of approximately $734,000 and working capital of approximately $3.25 million. The 2017-19 Strategic Business Plan (“Strat Plan”) was presented to and approved by the Board of Directors on December 12, 2016. The plan outlines the Company’s business objectives for the next three years and sets measurable targets for new product releases, sales and marketing programs to increase market penetration for the Company’s products and operational expense management. Implementation of the Strat Plan began in January 2017 and management remains confident that the objectives are achievable. The Company anticipates achievement of a cash-flow positive position during the next twelve months based upon the revenue targets as outlined in the Strat Plan, the results of the private placement offering in March 2017 and the backing of a shareholder , During the year ended December 31, 2016, the Company significantly reduced operating expenses through a systematic review of operations throughout the organization. As a result, the Company achieved a reduction in its weekly operating cash requirements of approximately 19% to $80,253 (2015: $98,699). The Strat Plan assumes the weekly cash requirement will decline through the year ending December 31, 2017. The Company has achieved the reduction in weekly cash requirements by renegotiating contracts with key consultants and canceling consulting agreements where the cost-benefits are negligible, working with vendors to reduce or eliminate minimum purchasing requirements, to extend payment terms and re-sourcing materials when necessary to reduce costs. Production cost savings, especially direct manufacturing costs, have been realized by utilizing sub-contractors to perform labor intensive production processes. This improves efficiency for our manufacturing staff, allowing them to concentrate their efforts on more complex assembly and production tasks. During the six months ended June 30, 2017, the Company’s average weekly operating cash requirement was $99,740 (2016: $89,472). Payments to vendors and sub-contractors included in the December 31, 2016 accounts payable balance, a significant royalty payment that had been deferred in 2016 as part of a legal settlement and other payments for contractual obligations has resulted in a higher than expected rate as compared to the year ended December 31, 2016. Many of these items are one-time events and the Company anticipates the cash requirements to revert to $80,000 to $85,000 per week by the end of 2017. Barring any unforeseen circumstances, the Company believes that it is probable that it will be able to meet its obligations as they fall due within one year after the financial statements are issued.

Fair Value Measurement - Market

Fair Value Measurement - Marketable Securities	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Fair Value Measurement - Marketable Securities	Note 5 - Fair Value Measurement - Marketable Securities Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2017 and December 31, 2016. Money Market Funds and Municipal Securities: As of June 30, 2017 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 228 $ - $ - $ - $ 228 Municipal securities 1,009,356 1,030 1,009 - 1,011,395 Total Level 2: 1,009,584 1,030 1,009 - 1,011,623 Total: $ 1,009,584 $ 1,030 $ 1,009 $ - $ 1,011,623 As of December 31, 2016 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 29,657 $ 15 $ - $ - $ 29,672 Municipal securities 20,314 15 - - 20,329 Total Level 2: 49,971 30 - - 50,001 Total: $ 49,971 $ 30 $ - $ - 50,001 Marketable securities include money market funds and municipal securities which are classified as available for sale. The securities are valued at fair market value. Maturities of the securities are less than one year. Unrealized gains relating to the available for sale investment securities were recorded in the Condensed Consolidated Statement of Changes in Stockholders’ Equity as comprehensive income. These amounts were $852 and $1,009 (net of effect of income tax expense of $-) for the three and six months ended June 30, 2017 and an unrealized loss of $2,006 and unrealized gain of $6,528 for the three and six months ended June 30, 2016. Proceeds from the sale of marketable securities in the three and six months ended June 30, 2017 and 2016 were $650,661 and $1,745,554 and $900,863 and $2,502,319 for the three and six months ended June 30, 2016. Gross gains, resulting from these sales, amounted to $605 and $1,844 for the three months ended June 30, 2017 and 2016 and $1,656 and $2,152 for the six months ended June 30, 2017 and 2016.

Trade Receivables - Related Par

Trade Receivables - Related Party	6 Months Ended
	Jun. 30, 2017
Receivables [Abstract]
Trade Receivables - Related Party	Note 6 - Trade Receivables – Related Party (restated) Trade receivables – related party are made up of amounts due from Hainan Savy Akers Biosciences Ltd (“Hainan”), a joint venture between Akers, Thomas Knox, Akers’ former Board Chairman, and Hainan Savy Investment Management Ltd, located in the People’s Republic of China. The Company holds a 19.9% position in the joint venture. The amount due is non-interest bearing, unsecured and generally has a term of 30-90 days (Note 14).

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories	Note 7 – Inventories (restated) Inventories consists of the following categories: June 30, 2017 December 31, 2016 (restated) Raw Materials $ 487,209 $ 440,316 Sub-Assemblies 974,547 907,989 Finished Goods 810,381 749,488 Reserve for Obsolescence (43,298 ) (61,272 ) $ 2,229,839 $ 2,036,521 Obsolete inventory charged to cost of goods during the three and six months ended June 30, 2017 totaled $21,542 and $21,542 and $- and $2,968 was charged for the three and six months ended June 30, 2016.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 8 - Property, Plant and Equipment Property, plant and equipment consists of the following: June 30, 2017 December 31, 2016 Computer Equipment $ 114,771 $ 114,771 Computer Software 40,681 40,681 Office Equipment 39,959 39,959 Furniture & Fixtures 38,356 29,939 Machinery & Equipment 1,138,134 1,126,134 Molds & Dies 851,254 834,480 Leasehold Improvements 222,593 222,593 2,445,748 2,408,557 Less Accumulated Depreciation 2,184,992 2,149,165 $ 260,756 $ 259,392 Depreciation expenses totaled $17,885 and $35,827 for the three and six months ended June 30, 2017 and $14,650 and $28,352 for the three and six months ended June 30, 2016.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 9 - Intangible Assets Intangible assets as of June 30, 2017 and December 31, 2016 and the movements for the periods then ended are as follows: Distributor & Patents & Customer Trademarks Relationships Totals Cost or Deemed Cost At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At June 30, 2017 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Amortization Charge 85,554 - 85,554 Disposals - - - At June 30, 2017 $ 1,410,775 $ 1,270,639 $ 2,681,414 Net Book Value At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 At June 30, 2017 $ 1,216,221 $ - $ 1,216,221 Amortization expense totaled $42,777 and $85,554 during the three and six months ended June 30, 2017 and $42,777 and $85,554 for the three and six months ended June 30, 2016. The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows: Period Amount 2017 $ 171,108 2018 $ 171,108 2019 $ 171,108 2020 $ 171,108 2021 $ 171,108

Trade and Other Payables

Trade and Other Payables	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Trade and Other Payables	Note 10 - Trade and Other Payables (restated) Trade and other payables consists of the following: June 30, 2017 December 31, 2016 (restated) Trade Payables $ 821,581 $ 923,311 Accrued Expenses 620,310 480,302 Deferred Compensation 59,750 59,750 $ 1,501,641 $ 1,463,363 Trade and other payables – related party are as follows: June 30, 2017 December 31, 2016 Trade Payables $ 33,911 $ 182,001 Accrued Expenses - 52,066 $ 33,911 $ 234,067 As of June 30, 2017, the Company owed ChubeWorkx Guernsey Limited, a major shareholder, a royalty of $30,751 (Note 14) which was paid on July 20, 2017. As of June 30, 2017, the Company owed Hainan $670. Senior management at Hainan are actively involved in two other companies, Shenzhen Savy-Akers Biosciences (“Shenzhen”) and Dong Guan Senming E&P (“Senming”) which are therefore being included as related parties. The Company owed these two companies $2,490 as of June 30, 2017. Trade and other payables are non-interest bearing and are normally settled on 30 – 60 day terms.

Share-based Payments

Share-based Payments	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Payments	Note 11 - Share-based Payments On January 23, 2014, upon effectiveness of the registration statement filed with the SEC, the Company adopted the 2013 Stock Incentive Plan (the “Plan”) which provides for the issuance of up to 400,000 shares. The purpose of the Plan is to provide additional incentive to those officers, employees, consultants and non-employee directors of the Company and its parents, subsidiaries and affiliates whose contributions are essential to the growth and success of the Company’s business. On January 9, 2015, the Board of Directors of the Company approved, upon recommendation from the Compensation Committee of the Board, by unanimous written consent the Amended and Restated 2013 Incentive Stock and Award Plan (the “Amended Plan”), which increased the number of authorized shares of common stock subject to the Plan to 800,000 shares. On September 30, 2016, the Board of Directors increased the number of authorized shares of common stock subject to the Amended Plan to 830,000 shares. As of June 30, 2017, under the 2013 Amended Plan, grants of restricted stock and options to purchase 268,166 shares of common stock have been issued and are unvested or unexercised and 3,292 shares of common stock remain available for grants. The Amended Plan may be administered by the board or a board-appointed committee. Eligible recipients of option awards are employees, officers, consultants or directors (including non-employee directors) of the Company or of any parent, subsidiary or affiliate of the Company. The board has the authority to grant to any eligible recipient any options, restricted stock or other awards valued in whole or in part by reference to, or otherwise based on, the Company’s common stock. Qualified option holders may exercise their options at their discretion. Each option granted may be exchanged for a prescribed number of shares of common stock. The Company did not issue any options or warrants under the above plan during the three and six months ended June 30, 2017. The following table summarizes the option activities for the six months ended June 30, 2017: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Shares Exercise Price Term (years) Value Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Granted - - - - Exercised - - - - Forfeited - - - - Canceled/Expired - - - - Balance at June 30, 2017 259,000 $ 4.23 2.55 $ 600 Exercisable as of June 30, 2017 241,667 $ 4.30 2.44 $ 600 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $1.25 for our common shares on June 30, 2017. A summary of the Company’s non-vested shares as of June 30, 2017 and the changes during the period then ended are as follows: Weighted Average Grant Non-Vested Shares Shares Date Fair Value Non-vested at January 1, 2017 19,834 $ 2.36 Granted - - Vested (2,500 ) 1.05 Forfeited - - Non-vested at June 30, 2017 17,334 $ 2.36 Unrecognized compensation cost related to non-vested employee stock options totaled $23,167 as of June 30, 2017. The cost is to be recognized over a weighted average period of 1.13 years. During the three and six months ended June 30, 2017, the Company incurred stock option expenses totaling $7,275 and $12,367. No stock option expenses were incurred in the three and six months ended June 30, 2016. During the six months ended June 30, 2017, the Company issued 894,750 warrants in conjunction with a public offering of its common shares in January 2017 and an additional 796,620 warrants in connection a private placement of its common shares in March 2017. All warrants carry a five-year expiration term. The table below summarizes the warrant activity for the six months ended June 30, 2017: Weighted Weighted Average Average Remaining Number of Warrants Exercise Price Contractual Term (years) Balance at December 31, 2016 - $ - - Granted 1,691,370 1.88 - Exercised (200,800 ) 1.50 - Forfeited - - - Canceled/Expired - - - Balance at June 30, 2017 1,490,570 $ 1.73 4.65 Exercisable as of June 30, 2017 693,950 $ 1.47 4.54

Equity

Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Equity	Note 12 - Equity The holders of common shares are entitled to one vote per share at meetings of the Company. Holders of Series A convertible preferred shares are entitled to five votes per share at meetings of the Company. A restricted stock award is an award of common shares that are subject to certain restrictions during a specified period. Restricted stock awards are independent of option grants and are generally subject to forfeiture if employment terminates prior to the release of the restrictions. The grantee cannot transfer the shares before the restricted shares vest. Shares on non-vested restricted stock have the same voting rights as common stock, are entitled to receive dividends and other distributions thereon and are considered to be currently issued and outstanding. The Company’s restricted stock awards vest of a period of one to three years. The Company expenses the cost of the restricted stock awards, which is determined to be the fair market value of the shares at the date of grant, straight-line over the period during which the restrictions lapse. For these purposes, the fair market value of the restricted stock is determined based on the closing price of the Company’s common stock on the grant date. On June 8, 2016, the Company issued 27,500 restricted common shares to an officer in connection with his employment agreement. These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018. The fair value of these shares was $54,725 and was based on the share price on the date of the grant. $5,206 was recorded during the three months ended June 30, 2017 as administrative expense on the Condensed Consolidated Statement of Operations and Comprehensive Loss and the remaining $14,163 is reported as deferred compensation, a contra equity account, on the Condensed Consolidated Balance Sheet as of June 30, 2017. On January 13, 2017, the Company completed a public offering of 1,789,500 common shares, raising net proceeds of $1,652,994. Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,667,000 2,000,400 Over-Allotment 122,500 147,000 Gross Proceeds 2,147,400 Underwriter/Gunnar Expenses Discount 150,318 Legal Fees 60,000 Roadshow 1,783 Miscellaneous 34,005 Total 246,106 Akers Biosciences Expenses Legal & Accounting 197,813 Registration/Regulatory 50,487 Total 248,300 Net Proceeds 1,652,994 In addition to the common shares issued, the Company also issued 833,500 warrants with an exercise price of $1.50 per common share in support of the base offering and 61,250 warrants with an exercise price of $1.20 per common share. All of the warrants issued have a five-year term. During the three months ended March 31, 2017, warrant holders from the January 13, 2017 public offering executed 163,300 warrants with an exercise price of $1.50 per common share, raising net proceeds of $244,950. On March 30, 2017, the Company completed a private placement of 1,448,400 unregistered shares of common stock, raising net proceeds of $1,760,317. The unregistered shares were admitted to trading on June 30, 2017 upon notification from the Securities and Exchange Commission that the Registration Statement, filed April 19, 2017, had been deemed effective. Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,448,400 2,027,760 Gross Proceeds 2,027,760 Underwriter/Gunnar Expenses Discount 141,943 Legal Fees 50,000 Total 191,943 Akers Biosciences Expenses Legal & Accounting 75,000 Filing Fees 500 Total 75,500 Net Proceeds 1,760,317 In addition to the common shares issued, the Company also issued 796,620 warrants with an exercise price of $1.96 per common share with a five-year term. On April 11, 2017, the Company issued 10,000 restricted shares to a consultant for services to be rendered during the year ending December 31, 2017. These shares vested on the date of the grant. The fair value of these shares was $18,000 and was based on the share price on the date of the grant. The company recorded $5,455 during the three months ended June 30, 2017 as sales and marketing expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss. During the three months ended June 30, 2017, warrant holders from the January 13, 2017 public offering executed 37,500 warrants with an exercise price of $1.50 per common share, raising net proceeds of $56,250.

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Loss Per Share	Note 13 - Loss per share (restated) The calculation of basic and diluted loss per share at June 30, 2017 and 2016 was based on the net loss of $2,166,270 and $2,517,861. The basic and diluted weighted average number of common shares outstanding as of June 30, 2017 and 2016 was 7,943,168 and 5,426,153. Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period. Potential common shares consist of options and warrants. Diluted net loss per common share was the same as basic net loss per common share for the six months ended June 30, 2017 and 2016 since the effect of options and warrants would be anti-dilutive due to the net loss. Instruments excluded from dilutive earnings per share, because their inclusion would be anti-dilutive, were as follows: incentive and award stock options – 259,000 (2016: 203,000); unvested restricted shares of common stock – 9,166 (2016: 18,333); warrants – 1,490,570 (2016: -) as of June 30, 2017.

Income Tax Expense

Income Tax Expense	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Expense	Note 14 - Income Tax Expense There is no income tax benefit for the losses for the six months ended June 30, 2017 and 2016 since management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of January 1, 2017, the Company had no unrecognized tax benefits, or any tax related interest or penalties. There were no changes in the Company’s unrecognized tax benefits during the six months ended June 30, 2017 related to unrecognized tax benefits. With few exceptions, the U.S. and state income tax returns filed for the tax years ended on December 31, 2013 and thereafter are subject to examination by the relevant taxing authorities.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 15 - Related Party Transactions (restated) On June 19, 2012, the Company entered into a 3-year exclusive License & Supply Agreement with ChubeWorkx Guernsey Limited (as successor to SONO International Limited) (“ChubeWorkx”) for the purchase and distribution of Akers’ proprietary breathalyzers outside North America. ChubeWorkx paid a licensing fee of $1,000,000 which was recognized over the term of the agreement through September 30, 2015. On June 13, 2013, the Company announced an expansion of the License and Supply Agreement with ChubeWorkx to include worldwide marketing and distribution of the “Be CHUBE” program using the Company’s breathalyzer. On August 17, 2016, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with ChubeWorkx Guernsey Limited (“ChubeWorkx”), a major shareholder, which settled all pending claims between the Company and ChubeWorkx. Specifically, the Company and ChubeWorkx agreed to voluntarily dismiss (i) the action in the United States Federal Court, District of New Jersey brought by the Company against ChubeWorkx for outstanding amounts due to the Company under a promissory note and (ii) the action in The High Court of Justice, Queen’s Bench Division Commercial Court, Royal Courts of Justice, United Kingdom brought by ChubeWorkx against the Company arising from an exclusive licensing agreement between ChubeWorkx and the Company (“Licensing Agreement”). Under the terms of the Settlement Agreement, the Company will recover the full outstanding principal amount in the year of the settlement in the form of $750,000 of BreathScan® Alcohol Detector inventory – which the Company intends to subsequently sell – and the balance of $549,609 as prepaid royalty. Akers’ established an allowance for this doubtful note in the Company’s financial statements for the year ended December 31, 2015. As a result of the Settlement Agreement, the Company reversed the allowance for doubtful note in the amount of $1,299,609 which was included in the Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2016. In addition to addressing the promissory note described above, the Settlement Agreement also allows the Company to market and sell all of the Company’s breath technology tests worldwide, unencumbered by any past/future claims by ChubeWorkx under the Licensing Agreement (entered into with ChubeWorkx in 2012 and subsequently amended in 2013). Under the terms of the Settlement Agreement, ChubeWorkx no longer holds any rights pertaining to Akers’ BreathScan® technology, which serves as the basis for a number of commercialized products including BreathScan® Alcohol Detector and BreathScan OxiChek™; and a number of products in development. In return for the Company regaining the full rights to sell breath technology products, under the terms of the Settlement Agreement, ChubeWorkx is entitled to receive a royalty of 5% of the Company’s gross revenues (the “ChubeWorkx Royalty”) until ChubeWorkx has earned an aggregate $5,000,000, after which point ChubeWorkx will no longer be entitled to receive any royalties from the Company and the Company shall have no further obligation to ChubeWorkx. The Settlement Agreement further allows the Company to retain 50% of the ChubeWorkx Royalty until the full $549,609 cash component of the monies owed by ChubeWorkx to the Company as described above has been satisfied. The Company recorded royalty expenses of $61,502 and $93,781 for the three and six months ended June 30, 2017 which are included in sales and marketing expenses – related party on the Condensed Consolidated Statement of Operations and Comprehensive Loss. Other terms of the Settlement include: 1) the pledge as security of all earned but unpaid royalties by the Company to ChubeWorkx all Company assets, worthy to satisfy its obligations, including all inventory and receivables, with the exception of (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; 2) the pledge as security of the settlement sum which remains unpaid by the Company to ChubeWorkx all Company (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; and 3) the grant of voting proxy by ChubeWorkx to the Company which allows the Company to vote ChubeWorkx’s shares for corporate formalities under certain conditions. The pledged assets are only at risk in the event that the Company cannot satisfy any outstanding royalty payment obligations subject to various cure periods and/or through a restructuring and/or liquidation under the United States Bankruptcy laws of the Company in favor of payment of said obligation. The Company began purchasing manufacturing molds, plastic components and the assembled BreathScan Lync™ device through Hainan and its related parties during the year ended December 31, 2016 (Note 9). The Company purchased a total of $- and $30,043 during the three months ended June 30, 2017 and 2016 and $16,774 and $30,043 for the six months ended June 30, 2017 and 2016 from this related party. As of June 30, 2017, the Company owed the three companies $3,160 which is included in trade and other payables – related party on the Condensed Consolidated Balance Sheet. Trade receivables – related party as of June 30, 2017 and December 31, 2016 were $- and $31,892. The amounts due are non-interest bearing, unsecured and generally have a term of 30-180 days (Note 6). Product revenue – related party for the three months ended June 30, 2017 and 2016 were $(24,064) and $- and total $- and $- for the six months then ended. The revenue was the result of sales to Hainan and its related parties.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 16 – Commitments (restated) The Company leases its facility in West Deptford, New Jersey under an operating lease (“Thorofare Lease”) with annual rentals of $132,000 plus common area maintenance (CAM) charges. The lease, which took effect on January 1, 2008, reduced the CAM charges allowing the Company to reach their own agreements with utilities and other maintenance providers. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31, 2019. Rent expense for the Thorofare Lease, including related CAM charges for the three months ended June 30, 2017 and 2016 totaled $40,440 and $40,290, respectively. Rent expenses for the Thorofare Lease, including related CAM charges totaled $80,927 and $80,580 for the six months ended June 30, 2017 and 2016. The Company entered into a 24-month lease for a satellite office located in Ramsey, New Jersey (“Ramsey Lease”) with annual rents of $25,980 plus common area maintenance (CAM) charges. The lease took effect on June 1, 2017 and runs through May 31, 2019. Rent expenses for the Ramsey Lease for the three and six months ended June 30, 2017 totaled $2,165. The Company posted a security deposit of $4,330 which is included in other assets on the Condensed Consolidated Balance Sheet. The Company entered into a 60-month operating lease for equipment with annual rentals of $6,156 on September 29, 2014. The lease commenced on October 21, 2014 upon the delivery of the equipment. The schedule of lease commitments is as follows: Thorofare Ramsey Equipment Lease $ Lease $ Lease $ Total $ Next 12 Months 132,000 25,980 6,156 164,136 Next 13-24 Months 132,000 23,815 6,156 161,971 Next 25-36 Months 66,000 - 2,052 68,052 On June 30, 2017, the Company signed the Third Amendment to the exclusive Distribution Agreement with NovoTek Pharmaceuticals Limited (‘NovoTek’) which expanded the geographic area of coverage to include Poland and grants NovoTek the right to assemble certain PIFA Heparin PF/4 products in their facilities from components acquired from the Company. The Company has agreed to provide PIFA Heparin/PF4 devices, valued at approximately $88,500, at no charge to NovoTek for their use and are to be shipped upon their request. Capitalized during the three months ended June 30, 2017, the Company incurred a charge to product cost of sales of $88,500 in connection with this product obligation and included this amount as an accrued expense in trade and other payables within the Company’s condensed consolidated balance sheets as of June 30, 2017.

Major Customers

Major Customers	6 Months Ended
	Jun. 30, 2017
Major Customers [Abstract]
Major Customers	Note 17 - Major Customers (restated) For the three months ended June 30, 2017, two customers generated 10% or more of the Company’s revenue. Sales to these customers accounted for 74% of the Company’s revenue. As of June 30, 2017, the amount due from these customers was $701,826 of which $500,000 has an extended term of 180 days. This concentration makes the Company vulnerable to a near-term severe impact should the relationships be terminated. For the six months ended June 30, 2017, three customers generated 10% or more of the Company’s revenue. Sales to these customers accounted for 73% of the Company’s revenue. As of June 30, 2017, the amount due from these customers was $768,306 of which $500,000 has an extended term of 180 days. This concentration makes the Company vulnerable to a near-term severe impact should the relationships be terminated. For the three months ended June 30, 2016, two customers each generated more than 10% of the Company’s product revenue. In aggregate, sales to these customers accounted for 79% of the Company’s product revenue. As of June 30, 2016, the amount due from these two customers was $96,390. For the six months ended June 30, 2016, three customers each generated more than 10% of the Company’s product revenue. In aggregate, sales to these customers accounted for 82% of the Company’s product revenue. As of June 30, 2016, the amount due from these three customers was $488,456. This concentration makes the Company vulnerable to a near-term severe impact should the relationships be terminated.

Major Suppliers

Major Suppliers	6 Months Ended
	Jun. 30, 2017
Major Suppliers [Abstract]
Major Suppliers	Note 18 - Major Suppliers For the three months ended June 30, 2017, two suppliers accounted for 10% or more of the Company’s purchases. These suppliers accounted for 30% of the Company’s total purchases. As of June 30, 2017, the amount due to these suppliers was $42,742. For the six months ended June 30, 2017, one supplier accounted for 10% or more of the Company’s purchases. This supplier accounted for 14% of the Company’s total purchases. As of June 30, 2017, the amount due to this supplier was $-. For the three months ended June 30, 2016, two suppliers each accounted for more than 10% of the Company’s purchases. In aggregate, these suppliers accounted for 32% of the Company’s total purchases. As of June 30, 2016, the amount due to the suppliers was $20,445. For the six months ended June 30, 2016, no suppliers accounted for more than 10% of the Company’s purchases.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 19 – Contingencies On October 17, 2016 the Company was served with a notice that Pulse Health LLC (“Pulse”) filed a lawsuit against the Company on September 30, 2016 in United States Federal District Court, District of Oregon, alleging a breach of contract under the settlement agreement entered into by the Company and Pulse on April 8, 2011 which settled all claims and disputes between the Company and Pulse arising from a previously executed Technology Development Agreement entered into by the Company and Pulse and damages resulting from said alleged breach. Additionally, Pulse alleges false advertising and unlawful trade practices in connection with the Company’s sales activities related to the Company’s OxiChek™ products. The Company filed a series of motions with the Court seeking (1) to dismiss the Pulse complaint for lack of jurisdiction or, in the alternative, transfer the matter to the District Court for the District of New Jersey, Camden Vicinage and (2) to dismiss the unfair competition claims for failure to state a claim on which relief could be granted. Oral arguments on these motions were heard by the Court on March 10, 2017. The Court decided by order dated April 14, 2017 in favor of the Company and has dismissed with prejudice the claims brought by Pulse for unfair competition (both federal and state counts). The court decided against the Company in its motions for transfer of venue and for lack of jurisdiction. As such, the case shall proceed in the District Court of Oregon with discovery commencing in late April. Pulse subsequently filed an Amended Complaint, in which Pulse seeks not less than $500,000 in damages and, among other items, an injunction prohibiting the Company from manufacture, use and sale of the OxiChek product. The Company answered the Amended Complaint on May 30, 2017. Discovery has commenced and is scheduled to conclude on October 2, 2017. The Court has set the trial date for July 17, 2018. The Company intends to establish a rigorous defense of all claims. As the case has not progressed beyond initial motion practice and early discovery, the Company is unable to assess the potential outcome, no accrual for losses was made as of June 30, 2017. All legal fees were expensed as and when incurred.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Information	Note 20 – Segment Information (restated) The Company is organized and operates as one operating segment. In accordance with FASB ASC 280 “Segment Reporting”, the Chief Operating Officer is the chief operating decision-maker who reviews operating results to make decisions on allocation of resources and assessment of performance for the entire company. The total revenue by different product lines was as follows: Three months ended Six months ended June 30, June 30, Product Line 2017 2016 2017 2016 (restated) (restated) MicroParticle Catalyzed Biosensor (“MPC”) $ 69,848 $ 44,918 $ 155,507 $ 109,702 Particle ImmunoFiltration Assay (“PIFA”) 426,747 879,081 987,668 1,514,256 Other 576,266 32,487 596,936 70,552 Total Revenue $ 1,072,861 $ 956,486 $ 1,740,111 $ 1,694,510 The total revenue by geographic area determined based on the location of the customers was as follows: Three months ended Six months ended June 30, June 30, Geographic Region 2017 2016 2017 2016 (restated) (restated) United States $ 512,257 $ 452,756 $ 1,129,482 $ 1,118,961 People’s Republic of China 478,205 473,853 502,268 506,398 Rest of World 82,399 29,877 108,361 69,151 Total Revenue $ 1,072,861 $ 956,486 $ 1,740,111 $ 1,694,510 The Company had long-lived assets totaling $62,954 and $61,081 located in the People’s Republic of China and $1,414,023 and $1,500,086 located in the United States as of June 30, 2017 and December 31, 2016, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 21 - Subsequent Events On August 7, 2017, the Company’s shareholders approved the 2017 Equity Incentive Plan (“Plan”) which provides 1,350,000 common shares to encourage and enable the officers, employees, directors, consultants and other key persons of the Company, upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business, to acquire a proprietary interest in the Company. On August 7, 2017, the Shareholders elected Bill J. White, Richard C. Tarbox III and Christopher C. Schreiber to serve as non-executive directors and re-elected Raymond F. Akers and elected John J. Gormally as executive directors for the Company.

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP). Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed. As such, the information included in these financial statements should be read in conjunction with the audited financial statements as of and for the years ended December 31, 2016 and 2015 included in the Company’s 2016 Form 10-K. In the opinion of the management, these consolidated financial statements include all adjustments, consisting of only normal recurring nature, necessary for a fair statement of the financial position of the Company as of June 30, 2017 and its results of operations and cash flows for the three and six months ended June 30, 2017 and 2016. The results of operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2017. The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements.
Use of Estimates and Judgments	(b) Use of Estimates and Judgments The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for revenue recognition, allowances for doubtful accounts, inventory write-downs, impairment of intangible assets and valuation of share based payments.
Functional and Presentation Currency	(c) Functional and Presentation Currency These consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information presented in U.S. Dollars has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from loans and cash balances denominated in Foreign Currencies, are recorded in the consolidated statement of operations and comprehensive loss.
Comprehensive Income (Loss)	(d) Comprehensive Income (Loss) The Company follows Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 220 in reporting comprehensive income (loss). Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income.
Cash and Cash Equivalents	(e) Cash and Cash Equivalents Cash and cash equivalents comprise cash balances. The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents. Bank overdrafts are shown as part of trade and other payables in the consolidated balance sheet.
Fair Value of Financial Instruments	(f) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities. The fair value of marketable securities is described in Note 3(c).
Fair Value Measurement – Marketable Securities	(g) Fair Value Measurement – Marketable Securities The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include ● quoted prices for similar assets or liabilities in active markets; ● quoted prices for identical or similar assets or liabilities in inactive markets; ● inputs other than quoted prices that are observable for the asset or liability; ● inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.
Trade Receivables, Trade Receivables – Related Party and Allowance for Doubtful Accounts	(h) Trade Receivables, Trade Receivables – Related Party and Allowance for Doubtful Accounts (restated) The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature. The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. As of June 30, 2017 and December 31, 2016, allowances for doubtful accounts for trade receivables were $192,435 and $1,010,196. Bad debt expenses for trade receivables were $5,380 and $47,741 for the three month and six months ended June 30, 2017 and $146,196 for the three and six months ended June 30, 2016.
Concentration of Credit Risk	(j) Concentration of Credit Risk (restated) The Company is exposed to credit risk in the normal course of business primarily related to trade receivables and cash and cash equivalents. All of the Company’s cash is maintained with Fulton Bank of New Jersey, Bank of America, NA and PayPal. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company placed $182,913 and $67,865 with Fulton Bank of New Jersey, $10,222 and $795 with Bank of America, NA and $4,040 and $4,040 with PayPal as of June 30, 2017 and December 31, 2016. No losses have been incurred in these accounts. Three customers accounted for 76% of trade receivables as of June 30, 2017. In order to limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition.
Inventories	(k) Inventories Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overheads based on normal operating capacity.
Property, Plant and Equipment	(l) Property, Plant and Equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the consolidated statement of operations and comprehensive loss. Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Leasehold Improvements Shorter of the remaining lease or estimated useful life Depreciation methods, useful lives and residual values are reviewed at each reporting date.
Intangible Assets	(m) Intangible Assets (i) Patents and Trade Secrets The Company has developed or acquired several diagnostic tests that can detect the presence of various substances in a person’s breath, blood, urine and saliva. Propriety protection for the Company’s products, technology and process is important to its competitive position. As of June 30 (ii) Patent Costs Costs associated with applying for patents are capitalized as patent costs. Once the patents are approved, the respective costs are amortized over their estimated useful lives (maximum of 17 years) on a straight-line basis. Patent pending costs for patents that are not approved are charged to operations the year the patent is rejected. In addition, patents may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life. (iii) Other Intangible Assets Other intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5
Recoverability of Long Lived Assets	(n) Recoverability of Long Lived Assets In accordance with FASB ASC 360-10-35 “Impairment or Disposal of Long-lived Assets”, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges) and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets.
Investments	(o) Investments In accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company’s ability to significantly influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the time of the investment based upon several factors including, but not limited to the following: a) Representation on the Board of Directors b) Participation in policy-making processes c) Material intra-entity transactions d) Interchange of management personnel e) Technological dependencies f) Extent of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small. The Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the cost method. Investments recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company’s ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for using the cost method to the equity method of valuation.
Revenue Recognition	(p) Revenue Recognition In accordance with FASB ASC 605, the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) the collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales when title passes to the customer based on shipping terms. The Company typically does not accept returns nor offer charge backs or rebates except for certain distributors. Revenue recorded is net of any discount, rebate or sales return. The accrual for estimated sales returns was $- as of June 30, 2017 and December 31, 2016. The Company implemented a standard dealer cost model during the year ended December 31, 2016 which includes a provision for rebates to the distributors under limited circumstances. The Company established an accrual of $24,294 and $41,120, which is a reduction of revenue as of June 30, 2017 and December 31, 2016. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $67,855 and $170,678 during the three and six months ended June 30, 2017 and $115,685 and $215,653 for the three and six months ended June 30, 2016 for rebates, which is included as a reduction of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. License fee revenue is recognized on a straight-line basis over the term of the license agreement. When the Company enters into arrangements that contain more than one deliverable, the Company allocates revenue to the separate elements under the arrangement based on their relative selling prices in accordance with FASB ASC 605-25.
Income Taxes	(q) Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.
Shipping and Handling Fees and Costs	(r) Shipping and Handling Fees and Costs The Company charges actual shipping plus a handling fee to customers, which amounted to $15,049 and $14,387 for the three months ended June 30, 2017 and 2016 and to $33,469 and $30,432 for the six months ended June 30, 2017 and 2016. These fees are classified as part of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as part of the cost of net revenue, which amounted to $31,393 and $47,570 for the three and six months ended June 30, 2017 and to $47,018 and $68,732 for the three and six months ended June 30, 2016.
Research and Development Costs	(s) Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred.
Stock-based Payments	(t) Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over shorter of the period over which services are to be received or the vesting period. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees”. Under FASB ASC 505-50, the Company determines the fair value of the stock warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock-based awards to non-employees on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the period which services are to be received. At the end of each financial reporting period, prior to vesting or prior to completion of services, the fair value of equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurement until the equity based payments are fully vested or the service is completed.
Basic and Diluted Earnings Per Share of Common Stock	(u) Basic and Diluted Earnings per Share of Common Stock Basic earnings per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share are computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock.
Reclassifications	(v) Reclassifications Certain prior year amounts have been reclassified to conform to the current year’s presentation.
Recently Adopted Accounting Pronouncements	(w) Recently Adopted Accounting Pronouncements As of June 30, 2017 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted	(x) Recently Issued Accounting Pronouncements Not Yet Adopted As the Company is an emerging growth company, it has elected to adopt recently issued standards based on effective dates applicable to nonpublic entities. All effective dates as mentioned in the following paragraphs refer to that applicable to nonpublic entities. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 and interim reporting periods within annual reporting periods beginning after December 15, 2019. Early application is permitted as of annual reporting periods beginning after December 15, 2016 including interim reporting periods within that reporting period. The Company is currently evaluating the effect of the amendments but it does not anticipate a material impact of its financial statements. The Company expects to use the modified retrospective adoption method. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation

Restatement of Previously Iss30

Restatement of Previously Issued Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Changes and Error Corrections [Abstract]
Schedule of Impact of Correction to Previously Reported	The table below sets forth the consolidated balance sheets, including the balances originally reported, corrections and the as restated balances: As of June 30, 2017 As Reported Correction As Restated Trade Receivables – Related Party, net $ 125,001 $ (125,001 ) $ - Inventories, net 2,166,699 62,140 2,228,839 Total Current Assets 4,906,089 (62,861 ) 4,843,228 Total Assets 6,562,562 (62,861 ) 6,499,701 Trade and Other Payables 1,413,141 88,500 1,501,641 Total Current Liabilities 1,447,052 88,500 1,535,552 Total Liabilities 1,447,052 88,500 1,535,552 Accumulated Deficit (99,495,455 ) (151,361 ) (99,646,816 ) Total Stockholder’s Equity 5,115,510 (151,361 ) 4,964,149 Total Liabilities and Stockholders’ Equity 6,562,562 (62,861 ) 6,499,701 The table below sets for the consolidated statements of income, including the amounts originally reported, corrections, and the restated amounts: For the three months ended June 30, 2017 As Reported Correction As Restated Product revenue $ 1,097,295 $ (370 ) $ 1,096,925 Product revenue – Related party 100,567 (124,631 ) (24,064 ) Product Cost of Sales (264,231 ) (26,360 ) (290,591 ) Gross Income 933,631 (151,361 ) 782,270 Loss from Operations (669,301 ) (151,361 ) (820,662 ) Loss Before Income Taxes (666,647 ) (151,361 ) (818,008 ) Net Loss Attributable to Common Stockholders (666,647 ) (151,361 ) (818,008 ) Comprehensive Loss (665,795 ) (151,361 ) (817,156 ) Loss per share $ (0.08 ) $ (0.01 ) $ (0.09 ) For the six months ended June 30, 2017 As Reported Correction As Restated Product revenue $ 1,740,481 $ (370 ) $ 1,740,111 Product revenue – Related party 124,631 (124,631 ) - Product Cost of Sales (522,952 ) (26,360 ) (549,312 ) Gross Income 1,342,160 (151,361 ) 1,190,799 Loss from Operations (2,031,454 ) (151,361 ) (2,182,815 ) Loss Before Income Taxes (2,015,918 ) (151,361 ) (2,167,279 ) Net Loss Attributable to Common Stockholders (2,015,918 ) (151,361 ) (2,167,279 ) Comprehensive Loss (2,014,909 ) (151,361 ) (2,166,270 ) Loss per share $ (0.25 ) $ (0.02 ) $ (0.27 ) The table below sets forth the condensed consolidated statements of shareholders’ equity, including the balances originally reported, corrections and the as restated balances: For the six months ended June 30, 2017 As Reported Correction As Restated Net loss, for the six months ended June 30, 2017 $ (2,015,918 ) $ (151,361 ) $ (2,167,279 ) Accumulated Deficit, as of June 30, 2017 (99,495,455 ) (151,361 ) (99,646,816 ) Total Equity, as of June 30, 2017 5,115,510 (151,361 ) 4,964,149 The table below sets forth the condensed consolidated statements of cash flows from operating activities, including the balances originally reported, corrections and the as restated balances: For the six months ended June 30, 2017 As Reported Correction As Restated Net loss $ (2,015,918 ) $ (151,361 ) $ (2,167,279 ) (Increase)/decrease in trade receivables – related party (93,109 ) 125,001 31,892 Increase in inventories (151,720 ) (62,140 ) (213,860 ) Increase/(decrease) in trade and other payables (50,222 ) 88,500 38,278 Net cash used in operating activities (2,593,231 ) - (2,593,231 )

Basis of Presentation and Sig31

Basis of Presentation and Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Estimated Useful Life of Property Plant and Equipment	The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Leasehold Improvements Shorter of the remaining lease or estimated useful life
Schedule of Estimated Useful Lives for Current and Comparative Period	The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5

Fair Value Measurement - Mark32

Fair Value Measurement - Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Securities	This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings. As of June 30, 2017 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 228 $ - $ - $ - $ 228 Municipal securities 1,009,356 1,030 1,009 - 1,011,395 Total Level 2: 1,009,584 1,030 1,009 - 1,011,623 Total: $ 1,009,584 $ 1,030 $ 1,009 $ - $ 1,011,623 As of December 31, 2016 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 29,657 $ 15 $ - $ - $ 29,672 Municipal securities 20,314 15 - - 20,329 Total Level 2: 49,971 30 - - 50,001 Total: $ 49,971 $ 30 $ - $ - 50,001

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consists of the following categories: June 30, 2017 December 31, 2016 (restated) Raw Materials $ 487,209 $ 440,316 Sub-Assemblies 974,547 907,989 Finished Goods 810,381 749,488 Reserve for Obsolescence (43,298 ) (61,272 ) $ 2,229,839 $ 2,036,521

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consists of the following: June 30, 2017 December 31, 2016 Computer Equipment $ 114,771 $ 114,771 Computer Software 40,681 40,681 Office Equipment 39,959 39,959 Furniture & Fixtures 38,356 29,939 Machinery & Equipment 1,138,134 1,126,134 Molds & Dies 851,254 834,480 Leasehold Improvements 222,593 222,593 2,445,748 2,408,557 Less Accumulated Depreciation 2,184,992 2,149,165 $ 260,756 $ 259,392

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets as of June 30, 2017 and December 31, 2016 and the movements for the periods then ended are as follows: Distributor & Patents & Customer Trademarks Relationships Totals Cost or Deemed Cost At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At June 30, 2017 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Amortization Charge 85,554 - 85,554 Disposals - - - At June 30, 2017 $ 1,410,775 $ 1,270,639 $ 2,681,414 Net Book Value At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 At June 30, 2017 $ 1,216,221 $ - $ 1,216,221
Schedule of Estimated Aggregate Amortization Expense of Fiscal Years	The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows: Period Amount 2017 $ 171,108 2018 $ 171,108 2019 $ 171,108 2020 $ 171,108 2021 $ 171,108

Trade and Other Payables (Table

Trade and Other Payables (Tables)	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Schedule of Trade and Other Payable	Trade and other payables consists of the following: June 30, 2017 December 31, 2016 (restated) Trade Payables $ 821,581 $ 923,311 Accrued Expenses 620,310 480,302 Deferred Compensation 59,750 59,750 $ 1,501,641 $ 1,463,363
Schedule of Trade and Other Payables - Related Party	Trade and other payables – related party are as follows: June 30, 2017 December 31, 2016 Trade Payables $ 33,911 $ 182,001 Accrued Expenses - 52,066 $ 33,911 $ 234,067

Share-based Payments (Tables)

Share-based Payments (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Options Activity	The following table summarizes the option activities for the six months ended June 30, 2017: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Shares Exercise Price Term (years) Value Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Granted - - - - Exercised - - - - Forfeited - - - - Canceled/Expired - - - - Balance at June 30, 2017 259,000 $ 4.23 2.55 $ 600 Exercisable as of June 30, 2017 241,667 $ 4.30 2.44 $ 600
Schedule of Non Vested Share Activity	A summary of the Company’s non-vested shares as of June 30, 2017 and the changes during the period then ended are as follows: Weighted Average Grant Non-Vested Shares Shares Date Fair Value Non-vested at January 1, 2017 19,834 $ 2.36 Granted - - Vested (2,500 ) 1.05 Forfeited - - Non-vested at June 30, 2017 17,334 $ 2.36
Summary of Warrant Activity	The table below summarizes the warrant activity for the six months ended June 30, 2017: Weighted Weighted Average Average Remaining Number of Warrants Exercise Price Contractual Term (years) Balance at December 31, 2016 - $ - - Granted 1,691,370 1.88 - Exercised (200,800 ) 1.50 - Forfeited - - - Canceled/Expired - - - Balance at June 30, 2017 1,490,570 $ 1.73 4.65 Exercisable as of June 30, 2017 693,950 $ 1.47 4.54

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Schedule of Proceeds from Initial Public Offering	Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,667,000 2,000,400 Over-Allotment 122,500 147,000 Gross Proceeds 2,147,400 Underwriter/Gunnar Expenses Discount 150,318 Legal Fees 60,000 Roadshow 1,783 Miscellaneous 34,005 Total 246,106 Akers Biosciences Expenses Legal & Accounting 197,813 Registration/Regulatory 50,487 Total 248,300 Net Proceeds 1,652,994 Shares $ $ Common Shares Base Offering 1,448,400 2,027,760 Gross Proceeds 2,027,760 Underwriter/Gunnar Expenses Discount 141,943 Legal Fees 50,000 Total 191,943 Akers Biosciences Expenses Legal & Accounting 75,000 Filing Fees 500 Total 75,500 Net Proceeds 1,760,317

Commitments (Tables)

Commitments (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Commitments	The schedule of lease commitments is as follows: Thorofare Ramsey Equipment Lease $ Lease $ Lease $ Total $ Next 12 Months 132,000 25,980 6,156 164,136 Next 13-24 Months 132,000 23,815 6,156 161,971 Next 25-36 Months 66,000 - 2,052 68,052

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of Revenue by Different Product Lines	The total revenue by different product lines was as follows: Three months ended Six months ended June 30, June 30, Product Line 2017 2016 2017 2016 (restated) (restated) MicroParticle Catalyzed Biosensor (“MPC”) $ 69,848 $ 44,918 $ 155,507 $ 109,702 Particle ImmunoFiltration Assay (“PIFA”) 426,747 879,081 987,668 1,514,256 Other 576,266 32,487 596,936 70,552 Total Revenue $ 1,072,861 $ 956,486 $ 1,740,111 $ 1,694,510
Schedule of Revenue by Geographic Area Determined Based on Location of Customers	The total revenue by geographic area determined based on the location of the customers was as follows: Three months ended Six months ended June 30, June 30, Geographic Region 2017 2016 2017 2016 (restated) (restated) United States $ 512,257 $ 452,756 $ 1,129,482 $ 1,118,961 People’s Republic of China 478,205 473,853 502,268 506,398 Rest of World 82,399 29,877 108,361 69,151 Total Revenue $ 1,072,861 $ 956,486 $ 1,740,111 $ 1,694,510

Restatement of Previously Repor

Restatement of Previously Reported Financial Statements - Schedule of Impact of the Correction to the Previously Reported (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Trade Receivables - Related Party, net					$ 31,892
Inventories, net	2,228,839		2,228,839		2,036,521
Total Current Assets	4,843,228		4,843,228		3,186,944
Total Assets	6,499,701		6,499,701		5,085,107
Trade and Other Payables	1,501,641		1,501,641		1,463,363
Total Current Liabilities	1,535,552		1,535,552		1,697,430
Total Liabilities	1,535,552		1,535,552		1,697,430
Accumulated Deficit	(99,646,816)		(99,646,816)		(97,479,537)
Total Stockholder's Equity	4,964,149		4,964,149		3,387,677
Total Liabilities and Stockholders' Equity	6,499,701		6,499,701		5,085,107
Product revenue	1,096,925	$ 956,486	1,740,111	$ 1,694,510
Product revenue - Related party	(24,064)
Product Cost of Sales	(290,591)	(276,848)	(549,312)	(476,876)
Gross Income	782,270	679,638	1,190,799	1,217,634
Loss from Operations	(820,662)	(1,014,802)	(2,182,815)	(2,531,760)
Loss Before Income Taxes	(818,008)	(1,008,932)	(2,167,279)	(2,517,861)
Net Loss Attributable to Common Stockholders	(818,008)	(1,008,932)	(2,167,279)	(2,517,861)
Comprehensive Loss	$ (817,156)	$ (1,010,938)	$ (2,166,270)	$ (2,511,333)
Loss per share	$ (0.09)	$ (0.19)	$ (0.27)	$ (0.46)
(Increase)/decrease in trade receivables - related party			$ 31,892
Increase in inventories			(213,860)	(85,588)
Increase/(decrease) in trade and other payables			38,278	(103,029)
Net cash used in operating activities			(2,593,231)	$ (2,415,742)
Accumulated Deficit [Member]
Total Stockholder's Equity	$ (99,646,816)		(99,646,816)		$ (97,479,537)
As Reported [Member]
Trade Receivables - Related Party, net	125,001		125,001
Inventories, net	2,166,699		2,166,699
Total Current Assets	4,906,089		4,906,089
Total Assets	6,562,562		6,562,562
Trade and Other Payables	1,413,141		1,413,141
Total Current Liabilities	1,447,052		1,447,052
Total Liabilities	1,447,052		1,447,052
Accumulated Deficit	(99,495,455)		(99,495,455)
Total Stockholder's Equity	5,115,510		5,115,510
Total Liabilities and Stockholders' Equity	6,562,562		6,562,562
Product revenue	1,097,295		1,740,481
Product revenue - Related party	100,567		124,631
Product Cost of Sales	(264,231)		(522,952)
Gross Income	933,631		1,342,160
Loss from Operations	(669,301)		(2,031,454)
Loss Before Income Taxes	(666,647)		(2,015,918)
Net Loss Attributable to Common Stockholders	(666,647)		(2,015,918)
Comprehensive Loss	$ (665,795)		$ (2,014,909)
Loss per share	$ (0.08)		$ (0.25)
(Increase)/decrease in trade receivables - related party			$ (93,109)
Increase in inventories			(151,720)
Increase/(decrease) in trade and other payables			(50,222)
Net cash used in operating activities			(2,593,231)
As Reported [Member] | Accumulated Deficit [Member]
Total Stockholder's Equity	$ (99,495,455)		(99,495,455)
Correction [Member]
Trade Receivables - Related Party, net	(125,001)		(125,001)
Inventories, net	62,140		62,140
Total Current Assets	(62,861)		(62,861)
Total Assets	(62,861)		(62,861)
Trade and Other Payables	88,500		88,500
Total Current Liabilities	88,500		88,500
Total Liabilities	88,500		88,500
Accumulated Deficit	(151,361)		(151,361)
Total Stockholder's Equity	(151,361)		(151,361)
Total Liabilities and Stockholders' Equity	(62,861)		(62,861)
Product revenue	(370)		(370)
Product revenue - Related party	(124,631)		(124,631)
Product Cost of Sales	(26,360)		(26,360)
Gross Income	(151,361)		(151,361)
Loss from Operations	(151,361)		(151,361)
Loss Before Income Taxes	(151,361)		(151,361)
Net Loss Attributable to Common Stockholders	(151,361)		(151,361)
Comprehensive Loss	$ (151,361)		$ (151,361)
Loss per share	$ (0.01)		$ (0.02)
(Increase)/decrease in trade receivables - related party			$ 125,001
Increase in inventories			(62,140)
Increase/(decrease) in trade and other payables			88,500
Net cash used in operating activities
Correction [Member] | Accumulated Deficit [Member]
Total Stockholder's Equity	$ (151,361)		$ (151,361)

Basis of Presentation and Sig42

Basis of Presentation and Significant Accounting Policies (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)Breathlyzers	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Allowances for doubtful accounts for trade receivables	$ 192,435		$ 192,435		$ 1,010,196
Bad debt expenses	5,380	$ 146,196	46,239	$ 146,196
Deferred revenue			24,294		41,120
Revenue recognition rebates expense	67,855	115,685	170,678	215,653
Shipping, handling and transportation costs	15,049	14,387	33,469	30,432
Cost of net revenue	31,393	$ 47,018	$ 47,570	$ 68,732
Trade Receivable [Member] | Three Customers [Member]
Concentration risk percentage			76.00%
Concentration risk, number of customer | Breathlyzers			3
Fulton Bank of New Jersey [Member]
Cash	182,913		$ 182,913		67,865
Bank of America [Member]
Cash	10,222		10,222		795
PayPal [Member]
Cash	4,040		$ 4,040		$ 4,040
Minimum [Member]
Normal credit terms extended to customers			30 days
Maximum [Member]
Normal credit terms extended to customers			90 days
Cash, FDIC insured amount	$ 250,000		$ 250,000
Maximum [Member] | Patents [Member]
Finite-lived intangible asset, useful life			17 years

Basis of Presentation and Sig43

Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Useful Life of Property Plant and Equipment (Details)	6 Months Ended
	Jun. 30, 2017
Plant and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Plant and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years
Furniture & Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture & Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Equipment & Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment & Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life Description	Shorter of the remaining lease or estimated useful life

Basis of Presentation and Sig44

Basis of Presentation and Significant Accounting Policies - Schedule of Estimated Useful Lives for Current and Comparative Period (Details)	6 Months Ended
	Jun. 30, 2017
Patents and Trademarks [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	12 years
Patents and Trademarks [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	17 years
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	5 years

Management Plan (Details Narrat

Management Plan (Details Narrative) - USD ($)	Jan. 13, 2017	Mar. 31, 2017	Mar. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Proceeds from public offering	$ 1,652,994	$ 1,700,000	$ 1,760,317
Proceeds from private placement		$ 1,800,000
Reduction in weekly operating cash, percentage						19.00%
Reduction in weekly operating cash, amount						$ 80,253	$ 98,699
Weekly operating cash requirement increased				$ 99,740	$ 89,472
Minimum [Member]
Weekly cash requirements				80,000
Maximum [Member]
Weekly cash requirements				85,000
August 10, 2017 [Member]
Cash and marketable securities				734,000
Working capital				$ 3,250,000

Fair Value Measurement - Mark46

Fair Value Measurement - Marketable Securities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Maturities of securities			1 year
Unrealized Gains/(Losses) on Marketable Securities	$ 852	$ (2,006)	$ 1,009	$ 6,528
Proceeds from the sale of marketable securities	650,661	900,863	1,745,554	2,502,319
Gross gain on securities	$ 605	$ 1,844	$ 1,656	$ 2,152

Fair Value Measurement - Mark47

Fair Value Measurement - Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Cost	$ 1,009,584	$ 49,971
Accrued Income	1,030	30
Unrealized Gains	1,009
Unrealized Losses
Fair Value	1,011,623	50,001
Fair Value, Inputs, Level 2 [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,009,584	49,971
Accrued Income	1,030	30
Unrealized Gains	1,009
Unrealized Losses
Fair Value	1,011,623	50,001
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	228	29,657
Accrued Income		15
Unrealized Gains
Unrealized Losses
Fair Value	228	29,672
Fair Value, Inputs, Level 2 [Member] | Municipal Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	1,009,356	20,314
Accrued Income	1,030	15
Unrealized Gains	1,009
Unrealized Losses
Fair Value	$ 1,011,395	$ 20,329

Trade Receivables - Related P48

Trade Receivables - Related Party (Details Narrative)	6 Months Ended
	Jun. 30, 2017
Minimum [Member]
Trade and other payables are non-interest bearing, terms	30 days
Maximum [Member]
Trade and other payables are non-interest bearing, terms	60 days
Hainan [Member] | Minimum [Member]
Trade and other payables are non-interest bearing, terms	30 days
Hainan [Member] | Maximum [Member]
Trade and other payables are non-interest bearing, terms	90 days
Hainan [Member] | People's Republic of China [Member]
Equity interest percentage	19.90%

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Inventory Disclosure [Abstract]
Cost of goods sold for obsolete inventory	$ 21,542		$ 21,542	$ 2,968

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw Materials	$ 487,209	$ 440,316
Sub-Assemblies	974,547	907,989
Finished Goods	810,381	749,488
Reserve for Obsolescence	(43,298)	(61,272)
Inventory, Net, Total	$ 2,228,839	$ 2,036,521

Property, Plant and Equipment51

Property, Plant and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 17,885	$ 14,650	$ 35,827	$ 28,352

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	$ 2,445,748	$ 2,408,557
Accumulated Depreciation	2,184,992	2,149,165
Property, Plant and Equipment, Net	260,756	259,392
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	114,771	114,771
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	40,681	40,681
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	39,959	39,959
Furniture & Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	38,356	29,939
Machinery & Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	1,138,134	1,126,134
Molds & Dies [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	851,254	834,480
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	$ 222,593	$ 222,593

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 42,777	$ 42,777	$ 85,554	$ 85,554

Intangible Assets - Schedule o

Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Cost or Deemed Cost, Beginning Balance			$ 3,897,635
Cost or Deemed Cost, Additions
Cost or Deemed Cost, Disposals
Cost or Deemed Cost, Ending Balance	$ 3,897,635		3,897,635
Accumulated Amortization, Beginning Balance			2,595,860
Accumulated Amortization, Amortization Charge	42,777	$ 42,777	85,554	$ 85,554
Accumulated Amortization, Disposals
Accumulated Amortization, Ending Balance	2,681,414		2,681,414
Net Book Value, Beginning Balance			1,301,775
Net Book Value, Ending Balance	1,216,221		1,216,221
Patents & Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost or Deemed Cost, Beginning Balance			2,626,996
Cost or Deemed Cost, Additions
Cost or Deemed Cost, Disposals
Cost or Deemed Cost, Ending Balance	2,626,996		2,626,996
Accumulated Amortization, Beginning Balance			1,325,221
Accumulated Amortization, Amortization Charge			85,554
Accumulated Amortization, Disposals
Accumulated Amortization, Ending Balance	1,410,775		1,410,775
Net Book Value, Beginning Balance			1,301,775
Net Book Value, Ending Balance	1,216,221		1,216,221
Distributor & Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost or Deemed Cost, Beginning Balance			1,270,639
Cost or Deemed Cost, Additions
Cost or Deemed Cost, Disposals
Cost or Deemed Cost, Ending Balance	1,270,639		1,270,639
Accumulated Amortization, Beginning Balance			1,270,639
Accumulated Amortization, Amortization Charge
Accumulated Amortization, Disposals
Accumulated Amortization, Ending Balance	1,270,639		1,270,639
Net Book Value, Beginning Balance
Net Book Value, Ending Balance

Intangible Assets - Schedule of

Intangible Assets - Schedule of Estimated Aggregate Amortization Expense of Fiscal Years (Details)	Jun. 30, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 171,108
2,018	171,108
2,019	171,108
2,020	171,108
2,021	$ 171,108

Trade and Other Payables (Detai

Trade and Other Payables (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Royalty expenses	$ 61,502	$ 32,279	$ 93,781
Minimum [Member]
Trade and other payables are non-interest bearing, terms					30 days
Maximum [Member]
Trade and other payables are non-interest bearing, terms					60 days
ChubeWorkx [Member] | July 20, 2017 [Member]
Due to related parties owned	30,751				$ 30,751
Hainan [Member]
Due to related parties owned	670				670
Shenzhen Savy-Akers Biosciences and Dong Guan Senming E&P [Member]
Due to related parties owned	$ 2,490				$ 2,490

Trade and Other Payables - Sche

Trade and Other Payables - Schedule of Trade and Other Payable (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Trade Payables	$ 821,581	$ 923,311
Accrued Expenses	620,310	480,302
Deferred Compensation	59,750	59,750
Trade and Other Payables, Total	$ 1,501,641	$ 1,463,363

Trade and Other Payables - Sc58

Trade and Other Payables - Schedule of Trade and Other Payables - Related Party (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Trade Payables	$ 33,911	$ 182,001
Accrued Expenses		52,066
Trade and Other Payables - Related Party	$ 33,911	$ 234,067

Share-based Payments (Details N

Share-based Payments (Details Narrative) - USD ($)	Jan. 23, 2014	Jan. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016	Jan. 09, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option issued
Aggregate intrinsic value exercise price of options						$ 1.25
Unrecognized compensation cost			$ 23,167			$ 23,167
Unrecognized compensation weighted average period						7 months 17 days
Stock options expenses			$ 7,275			$ 12,367
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants term						5 years
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued during the period		894,750
Private Placement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants issued during the period				796,620
2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of unvested stock available for grants			3,292			3,292
2013 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option to purchase shares of common stock						268,166
Amended And Restated 2013 Incentive Stock And Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period									800,000
Amended And Restated 2013 Incentive Stock And Award Plan [Member] | Board Of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period								830,000
Maximum [Member] | 2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option issued	400,000

Share-based Payments - Summary

Share-based Payments - Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares, Beginning | shares	259,000
Number of Shares, Granted | shares
Number of Shares, Exercised | shares
Number of Shares, Forfeited | shares
Number of Shares, Canceled/Expired | shares
Number of Shares, Ending | shares	259,000
Number of Shares, Exercisable | shares	241,667
Weighted Average Exercise Price, Beginning | $ / shares	$ 4.23
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Canceled/Expired | $ / shares
Weighted Average Exercise Price, Ending | $ / shares	4.23
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.30
Weighted Average Remaining Contractual Term, Beginning	3 years 18 days
Weighted Average Remaining Contractual Term, Ending	2 years 6 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	2 years 5 months 9 days
Aggregate Intrinsic Value, Beginning | $	$ 20,100
Aggregate Intrinsic Value, Ending | $	600
Aggregate Intrinsic Value, Exercisable | $	$ 600

Share-based Payments - Schedule

Share-based Payments - Schedule of Non Vested Share Activity (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares Non-vested, beginning | shares	19,834
Number of Shares, Granted | shares
Number of Shares, Vested | shares	(2,500)
Number of Shares, Forfeited | shares
Number of Shares, Non-vested, ending | shares	17,334
Weighted Average Grant Date Fair Value, beginning | $ / shares	$ 2.36
Weighted Average Grant Date Fair Value, Granted | $ / shares
Weighted Average Grant Date Fair Value, Vested | $ / shares	1.05
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Weighted Average Grant Date Fair Value, ending | $ / shares	$ 2.36

Share-based Payments - Summar62

Share-based Payments - Summary of Warrant Activity (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Number of Warrants, Granted | shares
Number of Warrants, Exercised | shares
Number of Warrants, Forfeited | shares
Number of Warrants, Canceled/Expired | shares
Weighted Average Exercise Price, Beginning	$ 4.23
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Canceled/Expired
Weighted Average Exercise Price, Ending	4.23
Weighted Average Exercise Price, Exercisable	$ 4.30
Weighted Average Remaining Contractual Term, Beginning	3 years 18 days
Weighted Average Remaining Contractual Term, Ending	2 years 6 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	2 years 5 months 9 days
Warrants [Member]
Number of Warrants, Beginning | shares
Number of Warrants, Granted | shares	1,691,370
Number of Warrants, Exercised | shares	(200,800)
Number of Warrants, Forfeited | shares
Number of Warrants, Canceled/Expired | shares
Number of Warrants, Ending | shares	1,490,570
Number of Warrants, Exercisable | shares	693,950
Weighted Average Exercise Price, Beginning
Weighted Average Exercise Price, Granted	1.88
Weighted Average Exercise Price, Exercised	1.50
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Canceled/Expired
Weighted Average Exercise Price, Ending	1.73
Weighted Average Exercise Price, Exercisable	$ 1.47
Weighted Average Remaining Contractual Term, Beginning	0 years
Weighted Average Remaining Contractual Term, Ending	4 years 7 months 24 days
Weighted Average Remaining Contractual Term, Exercisable	4 years 6 months 14 days

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)	May 03, 2017	Apr. 28, 2017	Apr. 21, 2017	Apr. 17, 2017	Apr. 11, 2017	Mar. 30, 2017	Jan. 13, 2017	Jun. 08, 2016	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 28, 2017	Mar. 27, 2017	Dec. 31, 2016
Administrative expense									$ 829,929		$ 816,244	$ 1,620,457	$ 1,739,806
Deferred compensation									$ 14,163	$ 19,369		14,163				$ 24,572
Issuance of common stock							$ 1,652,994					$ 1,652,994
Number of common shares							1,789,500
Number of warrant issued during period									833,500			833,500
Warrant exercise price									$ 1.50			$ 1.50
Restricted Stock [Member]
Issuance of common stock					$ 18,000
Number of warrant issued during period									37,500			37,500
Warrant exercise price									$ 1.50			$ 1.50
Proceeds from issuance of warrants					$ 5,455				$ 56,250
Number of shares issued for services					10,000
Public Offering [Member]
Number of warrant issued during period									61,250	163,300		61,250
Warrant exercise price									$ 1.20	$ 1.50		$ 1.20
Warrant term												5 years
Proceeds from issuance of warrants										$ 244,950
Private Placement [Member]
Number of warrant issued during period									796,620			796,620
Warrant exercise price									$ 1.96			$ 1.96
Warrant term						5 years
Unregistered shares of common stock						1,448,400
Proceeds from unregistered shares						$ 1,760,317
Officer [Member]
Number of restricted common stock shares issued during the period								27,500
Stock options vested rights description								These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018.
Fair value of shares based on share price on date of grant								$ 54,725
Warrant Holder [Member]
Number of warrant issued during period	3,500	4,000	10,000	20,000										3,300	160,000
Warrant exercise price	$ 1.50	$ 1.50	$ 1.50	$ 1.50										$ 1.50	$ 1.50
Proceeds from issuance of warrants	$ 5,250	$ 6,000	$ 15,000	$ 30,000

Equity - Schedule of Proceeds F

Equity - Schedule of Proceeds From Initial Public Offering (Details) - USD ($)	Jan. 13, 2017	Jan. 30, 2017	Mar. 31, 2017	Mar. 30, 2017	Jun. 30, 2017
Number of common shares	1,789,500
Number of common shares, value	$ 1,652,994				$ 1,652,994
Payments of Stock Issuance Costs	248,300			$ 75,500
Net Proceeds:	1,652,994		$ 1,700,000	1,760,317
Underwriter And Gunnar Expenses [Member]
Payments of Stock Issuance Costs	246,106			191,943
Underwriter And Gunnar Expenses [Member] | Underwriter Discount [Member]
Payments of Stock Issuance Costs	150,318			141,943
Underwriter And Gunnar Expenses [Member] | Gunnar Roadshow [Member]
Payments of Stock Issuance Costs	1,783
Underwriter And Gunnar Expenses [Member] | Gunnar Miscellaneous [Member]
Payments of Stock Issuance Costs	34,005
Underwriter And Gunnar Expenses [Member] | Underwriter Legal Fees [Member]
Payments of Stock Issuance Costs				50,000
Parent Company Expenses [Member] | Legal Accounting Expenses [Member]
Payments of Stock Issuance Costs	197,813	$ 75,000
Parent Company Expenses [Member] | Registration Expenses [Member]
Payments of Stock Issuance Costs	50,487
Parent Company Expenses [Member] | Filing Fees [Member]
Payments of Stock Issuance Costs		$ 500
Common Shares [Member]
Gross Proceeds	$ 2,147,400			$ 2,027,760
Common Shares [Member] | Base Offering [Member]
Number of common shares	1,667,000			1,448,400
Number of common shares, value	$ 2,000,400			$ 2,027,760
Common Shares [Member] | Over-Allotment [Member]
Number of common shares	122,500
Number of common shares, value	$ 147,000
Underwriter Legal Fees [Member] | Underwriter And Gunnar Expenses [Member]
Payments of Stock Issuance Costs	$ 60,000

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss			$ 2,166,270	$ 2,517,861
Basic and diluted weighted average number of common shares outstanding	8,882,326	5,427,261	7,943,168	5,426,153
Stock Option [Member]
Anti-dilutive securities excluded from earning per shares			259,000	203,000
Restricted Stock [Member]
Anti-dilutive securities excluded from earning per shares			9,166	18,333
Warrant [Member]
Anti-dilutive securities excluded from earning per shares			1,490,570

Income Tax Expense (Details Nar

Income Tax Expense (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Unrecognized tax benefits

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Aug. 17, 2016	Jun. 19, 2012	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Exclusive license and supply agreement term		3 years
License fees received		$ 1,000,000
Royalty expenses			$ 61,502	$ 32,279	$ 93,781
Sales and Marketing Expenses - Related Party			61,502				93,781
Payments to acquire plastic and electronic components					30,043		16,774	30,043
Trade and other payables			3,160				3,160
Trade receivables related party									$ 31,892
Product revenue from related party			(24,064)
Sales and Marketing [Member]
Related Party Transaction [Line Items]
Royalty expenses				$ 61,502			93,781
Settlement Agreement [Member]
Related Party Transaction [Line Items]
Recover full outstanding principal amount			750,000				750,000
Proceeds from notes payable							549,609
Allowance for doubtful note									$ 1,299,609
Settlement Agreement [Member] | ChubeWorkx [Member]
Related Party Transaction [Line Items]
Percentage of royalty received	5.00%
Royalty revenue	$ 5,000,000
Percentage of royalty retain	50.00%
Due to related parties owned			$ 549,609				$ 549,609

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	Sep. 29, 2014	Jan. 07, 2013	Jan. 01, 2008	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Operating leases rent expense net	$ 6,156		$ 132,000			$ 25,980
Lease agreement term	60 months	7 years				24 months
Lease expiration date		Dec. 31, 2019
Rent expense, including related CAM charges				$ 40,440	$ 40,290	$ 80,927	$ 80,580
Rent expense				2,165		2,165
Security deposit				4,330		4,330
NovoTek Pharmaceuticals Limited [Member]
Payment agreed under agreement, value				$ 88,500		88,500
Charges incurred for cost of sales						$ 88,500

Commitments - Schedule of Lease

Commitments - Schedule of Lease Commitments (Details)	Jun. 30, 2017USD ($)
Next 12 Months	$ 164,136
Next 13-24 Months	161,971
Next 25-36 Months	68,052
Thorofare [Member]
Next 12 Months	132,000
Next 13-24 Months	132,000
Next 25-36 Months	66,000
Ramsey [Member]
Next 12 Months	25,980
Next 13-24 Months	23,815
Next 25-36 Months
Equipment Lease [Member]
Next 12 Months	6,156
Next 13-24 Months	6,156
Next 25-36 Months	$ 2,052

Major Customers (Details Narrat

Major Customers (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)Breathlyzers	Jun. 30, 2016USD ($)Breathlyzers	Jun. 30, 2017USD ($)Breathlyzers	Jun. 30, 2016USD ($)
Customers Two [Member]
Concentration risk, percentage	10.00%	10.00%
Concentration risk, number of customer | Breathlyzers	2	2
Due from customers	$ 701,826	$ 96,390	$ 701,826	$ 96,390
Customers Two [Member] | Extended Term 180 Days [Member]
Due from customers	$ 500,000		$ 500,000
Customers Two [Member] | Sales Revenue, Net [Member]
Concentration risk, percentage	74.00%	79.00%
Customers Three [Member]
Concentration risk, percentage			10.00%	10.00%
Concentration risk, number of customer | Breathlyzers			3
Due from customers	$ 768,306	$ 488,456	$ 768,306	$ 488,456
Customers Three [Member] | Extended Term 180 Days [Member]
Due from customers	$ 500,000		$ 500,000
Customers Three [Member] | Sales Revenue, Net [Member]
Concentration risk, percentage			73.00%	82.00%

Major Suppliers (Details Narrat

Major Suppliers (Details Narrative)	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)Breathlyzers	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)Breathlyzers	Jun. 30, 2016USD ($)
Supplier Two [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage	10.00%
Concentration risk, number of suppliers | Breathlyzers	2
Due to suppliers	$ 42,742		$ 42,742
Supplier Two [Member] | Accounts Receivable [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage	30.00%
Supplier One [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage			10.00%
Concentration risk, number of suppliers | Breathlyzers			1
Due to suppliers
Supplier One [Member] | Accounts Receivable [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage			14.00%
Supplier Two [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage		10.00%
Due to suppliers		$ 20,445		$ 20,445
Supplier Two [Member] | Accounts Receivable [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage		32.00%
No Supplier [Member]
Share-based Goods and Nonemployee Services Transaction [Line Items]
Concentration risk percentage				10.00%

Contingencies (Details Narrativ

Contingencies (Details Narrative)	Oct. 17, 2016USD ($)
Pulse Health LLC [Member] | Maximum [Member]
Contingency damages seeking amount	$ 500,000

Segment Information (Details Na

Segment Information (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
People's Republic of China [Member]
Long-lived assets	$ 62,954	$ 61,081
United States [Member]
Long-lived assets	$ 1,414,023	$ 1,500,086

Segment Information - Schedule

Segment Information - Schedule of Revenue by Different Product Lines (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Product Revenue Total	$ 1,072,861	$ 956,486	$ 1,740,111	$ 1,694,510
License Fees
Total Revenue	1,072,861	956,486	1,740,111	1,694,510
MicroParticle Calalyzed Biosensor ("MPC") [Member]
Product Revenue Total	69,848	44,918	155,507	109,702
Particle ImmunoFiltration Assay ("PIFA") [Member]
Product Revenue Total	426,747	879,081	987,668	1,514,256
Other [Member]
Product Revenue Total	$ 576,266	$ 32,487	$ 596,936	$ 70,552

Segment Information - Schedul75

Segment Information - Schedule of Revenue by Geographic Area Determined Based on Location of Customers (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total Revenue	$ 1,072,861	$ 956,486	$ 1,740,111	$ 1,694,510
United States [Member]
Total Revenue	512,257	452,756	1,129,482	1,118,961
People's Republic of China [Member]
Total Revenue	478,205	473,853	502,268	506,398
Rest of World [Member]
Total Revenue	$ 82,399	$ 29,877	$ 108,361	$ 69,151

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - shares	Aug. 07, 2017	Jan. 13, 2017
Number of common stock shares isued		1,789,500
Subsequent Event [Member] | 2017 Equity Incentive Plan [Member]
Number of common stock shares isued	1,350,000